Denali Therapeutics (DNLI) Capital Leases: 2024-2025
Historic Capital Leases for Denali Therapeutics (DNLI) over the last 1 years, with Sep 2025 value amounting to $5.6 million.
- Denali Therapeutics' Capital Leases fell 1.37% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 1.37%. This contributed to the annual value of $5.6 million for FY2024, which is N/A change from last year.
- Per Denali Therapeutics' latest filing, its Capital Leases stood at $5.6 million for Q3 2025, which was down 0.41% from $5.6 million recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Capital Leases registered a high of $5.6 million during Q3 2024, and its lowest value of $5.6 million during Q3 2025.
- For the 2-year period, Denali Therapeutics' Capital Leases averaged around $5.6 million, with its median value being $5.6 million (2025).
- Data for Denali Therapeutics' Capital Leases shows a maximum YoY decreased of 1.37% (in 2025) over the last 5 years.
- Over the past 2 years, Denali Therapeutics' Capital Leases (Quarterly) stood at $5.6 million in 2024, then dropped by 1.37% to $5.6 million in 2025.
- Its Capital Leases was $5.6 million in Q3 2025, compared to $5.6 million in Q2 2025 and $5.6 million in Q1 2025.